Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SLS

SELLAS Life Sciences Group Inc

11.05

Aug 11 • 3:59 PM ET +0.01 (0.09%)

11.05

Aftermarket • 4:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: IDYA RCUS CGON TNGX CRNX KYMR BMRN RYTM INCY KRYS

| Held by: XBI VTI IWM VXF IWO VTWO VHT IWC LABU VFMO

Scroll to Statements

Index	RUT
Market Cap	2.06B
Enterprise Value	1.95B
Income	-29.46M
Sales	0.00M
Book/sh	0.59
Cash/sh	0.58
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Mar 24, 2011
Dividend Gr. 3/5Y	- -
Payout	-
Employees	13
IPO	Mar 12, 2008

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	18.65
P/C	19.18
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	17.22
Current Ratio	17.22
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.23
EPS next Y	-0.12
EPS next Q	-0.04
EPS this Y	16.00%
EPS next Y	40.48%
EPS next 5Y	-
EPS past 3/5Y	51.28% 34.92%
Sales past 3/5Y	- -
EPS Y/Y TTM	41.60%
Sales Y/Y TTM	-
EPS Q/Q	26.44%
Sales Q/Q	-
Earnings	May 12 AMC
EPS/Sales Surpr.	16.67% -

Insider Own	1.21%
Insider Trans	0.00%
Inst Own	34.79%
Inst Trans	9.71%
ROA	-39.50%
ROE	-43.58%
ROIC	-27.35%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.27%
SMA50	1.41%
SMA200	92.73%
Trades

Shs Outstand	186.03M
Shs Float	183.79M
Short Float	30.08%
Short Ratio	5.66
Short Interest	55.28M
52W High	15.88 -30.40%
52W Low	1.39 694.96%
Volatility	6.82% 9.93%
ATR (14)	1.08
RSI (14)	47.72
Beta	2.49
Rel Volume	0.44
Avg Volume	9.76M
Volume	4,289,495

Perf Week	-6.44%
Perf Month	-12.44%
Perf Quarter	110.48%
Perf Half Y	190.03%
Perf YTD	193.10%
Perf Year	617.53%
Perf 3Y	613.50%
Perf 5Y	15.71%
Perf 10Y	-99.91%
Recom	1.00
Target Price	27.50
Prev Close	11.04
Price	11.05
Change %	0.09%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-21	Initiated	Cantor Fitzgerald	Overweight	$18
Nov-01-18	Initiated	Oppenheimer	Outperform
Apr-02-18	Initiated	H.C. Wainwright	Buy	$11
Mar-19-18	Upgrade	Maxim Group	Hold → Buy	$13

Today 04:05AM	SLS Stock Rebounds Premarket After Worst Day In 3 Weeks Retail Awaits Very Special Earnings Update (Stocktwits)
Aug-05-26 01:17AM	Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive (Stocktwits)
Aug-03-26 09:29PM	SLS Stock Logs Best Day In Over 2 Weeks: Citigroup Builds Nearly $5M Stake Ahead Of Key AML Trial Trigger (Stocktwits) +12.09% +5.26%
04:46AM	SLS Stock Eyes Green Start To August After Nearly $6M In Fresh Institutional Buying: Retail Stays Bearish (Stocktwits)
Jul-31-26 12:32PM	SLS Stock In Spotlight After Vanguard Capital Discloses 5.19% Stake Retail Calls It Huge Vote Of Conviction As AML Trial Readout Nears (Stocktwits)
02:53AM	Loading…
Jul-30-26 02:53AM	SLS Stock Turns Green After 3-Day Rout: Five Investors Add Shares As Key AML Trial Nears Final Trigger (Stocktwits)
Jul-28-26 11:33PM	SLS Stock Heads For Worst Month In Over 2 Years But Retail Bulls Hold For AML Readout And Buyout Hopes (Stocktwits) -6.88%
01:06AM	SLS Stock Hits 1-Month Low On China Arbitration Blow Retail Bulls Call It A Nothingburger Ahead Of AML Readout (Stocktwits)
Jul-27-26 04:17AM	SLS Stock Climbs Premarket: Heres What Smart Money Is Doing As Sellas Nears Critical Phase 3 AML Readout (Stocktwits)
Jul-24-26 09:44AM	Sellas CEO Angelos Stergiou Says 100% Certain AI Can Be Used To Beat Cancer (Stocktwits) -8.27%
01:11AM	SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEOs Fox Appearance (Stocktwits)
Jul-23-26 02:27AM	SLS Stock July Rout Deepens: Pharma Bro Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas (Stocktwits)
Jul-21-26 10:18PM	SLS Stock Tracks Worst Month Since March: Investor Slashes Stake By Over 30% As Quiet Period Begins Ahead Of AML Readout (Stocktwits) -6.36%
12:08AM	SLS Stock Rises Overnight: Retail Thinks CEO Just Dropped Buyout Clues Ahead Of Fox Appearance (Stocktwits)
Jul-19-26 11:00PM	SLS Stock Jumps Ahead Of CEOs Fox Appearance: Retail Bets AML Readout Could Spark Big Pharma Bidding War (Stocktwits)
12:18AM	Loading…
Jul-17-26 12:18AM	SLS Stock Hits July Low As AML Readout Nears Retail Bulls See Stellar Hint In CEOs Fox Appearance Next Week (Stocktwits) +12.26%
Jul-16-26 03:12AM	SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot (Stocktwits) -8.13%
Jul-14-26 03:11AM	SLS Stock Jumps Overnight After New Investor Disclosure Retail Flags Massive Options Bet Ahead Of AML Data (Stocktwits) +6.10%
Jul-12-26 10:48PM	SLS Vs MLTX: Retail Traders Race To Pick Mercks Next Biotech Buyout As Keytrudas $31.7B Patent Cliff Nears (Stocktwits)
Jul-09-26 12:38AM	SLS Stock Snaps 2-Day Slide: Sellas SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY (Stocktwits)
Jul-08-26 01:03PM	SLS Stock In The Spotlight As CEO Pushes Back On Regal Trial Criticism Lets Separate The Noise From The Data (Stocktwits)
02:13AM	SLS Stock Logs 2-Day Losing Streak: Mixed Institutional Bets Emerge Ahead Of Key AML Trial Update (Stocktwits)
Jul-07-26 01:15AM	SLS Stock Rises Overnight: Why Retail Traders Prefer Sellas Over IBRX, ONDS, PYPL As Most Bullish Pick (Stocktwits)
Jul-05-26 09:27PM	SLS Stock Notches 3-Week Winning Run: MassMutual Opens Tiny Stake Ahead Of Key AML Readout (Stocktwits)
Jul-01-26 11:26PM	SLS Stock Sees Worst Day In Over A Month But Prediction Market Flashes 83% Odds For November AML Trial Success (Stocktwits) -10.09% +12.89%
01:35AM	SLS Stock Logs Record H1 As AML Trial Nears Finish Line Why Are Retail Traders Refusing To Cash Out? (Stocktwits)
Jun-29-26 10:38PM	Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today? (Stocktwits) +24.70%
09:08PM	SLS Stock Hits Over 5-Year High: Retail Traders Bet Big On Breaking $25 As AML Readout Looms (Stocktwits)
12:24AM	SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees Continued Opportunities In Immuno-Oncology (Stocktwits)
Jun-28-26 11:56PM	Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? (Stocktwits)
06:53AM	Loading…
Jun-26-26 06:53AM	SLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout Chatter (Stocktwits) +17.66%
Jun-25-26 12:24PM	SLS Stock Up 13% As Executive Severance Updates Reignite Buyout Speculation (Stocktwits) +14.83%
Jun-21-26 09:59PM	SLS Stock Slips Overnight: Shareholders Approve 20M New Shares, CEO Awarded 1M RSUs (Stocktwits)
Jun-16-26 11:09AM	All Eyes On SLS Stock Ahead Of Annual Shareholder Meet Whats On The Agenda? (Stocktwits)
Jun-05-26 04:51AM	SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute (Stocktwits) -8.96%
Jun-02-26 10:54AM	SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities A Look At The Important Numbers (Stocktwits) -8.16%
May-29-26 12:40AM	SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout (Stocktwits)
May-27-26 11:30PM	SLS Stock Extends Rally Overnight: CEO Says Bullish Leukemia Data Could Drive NCCN Recognition For GPS (Stocktwits) +5.67% +6.99%
May-26-26 11:21PM	SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms (Stocktwits)
07:26AM	SLS Stock Heads For Their Best Month This Year Ahead Of Key AML Trial Readout (Stocktwits)
07:26AM	SLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial Readout (Stocktwits)
May-21-26 11:54PM	SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst (Stocktwits) -15.72%
03:02AM	SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, Whole Gamut Of Cancer Uses For GPS (Stocktwits)
12:46AM	Why Did ARM, SLS, EBAY Stocks Surge To 52-Week Highs? (Stocktwits)
May-14-26 08:00AM	SELLAS Life Sciences to Participate in Upcoming Investor Conferences (GlobeNewswire) +13.63%
May-12-26 04:05PM	SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +25.10%
Apr-22-26 06:03PM	Inventiva Builds Up Leadership Team Ahead of Potential Commercialization (Exec Edge)
Mar-27-26 08:05AM	These 16 stocks are a short seller's dream - likely losers no matter what the market does (MarketWatch) -11.82%
Mar-19-26 04:05PM	SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +5.05% -8.46%
Mar-17-26 04:30PM	SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference (GlobeNewswire) -5.97%
Mar-12-26 08:35AM	SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 (GlobeNewswire) -8.21%
Mar-04-26 12:59PM	What's Going With SELLAS Life Sciences Stock On Wednesday? (Benzinga)
Jan-14-26 08:30AM	SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe (GlobeNewswire)
Dec-29-25 08:35AM	SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) (GlobeNewswire) +16.72%
Dec-07-25 06:00PM	SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 (GlobeNewswire)
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire) +12.99%
Nov-12-25 04:05PM	SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-25 09:00AM	SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-29-25 11:57AM	Sellas Life Sciences Group Inc. (SLS) Advances Cancer Pipeline with $31M Funding and Upcoming R&D Showcase (Insider Monkey)
Oct-27-25 08:30AM	SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds (GlobeNewswire)
Oct-22-25 09:00AM	SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum (GlobeNewswire)
Oct-13-25 08:00AM	SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 (GlobeNewswire)
Sep-30-25 08:30AM	SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update (GlobeNewswire)
Sep-11-25 08:30AM	SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds (GlobeNewswire)
Aug-12-25 04:05PM	SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 08:30AM	SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification (GlobeNewswire)
Jul-31-25 07:02PM	SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised) (Zacks)
Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire)
08:02AM	SELLAS CDK9 inhibitor to advance after exceeding expectations in AML (Clinical Trials Arena)
Jul-15-25 07:45AM	SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study (GlobeNewswire)
Jul-07-25 08:45AM	SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board (GlobeNewswire)
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire)
08:00AM	SELLAS Life Sciences to be Added to Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-23-25 12:00PM	Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +11.04%
Jun-05-25 08:45AM	SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts (GlobeNewswire)
Jun-02-25 08:00AM	SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting (GlobeNewswire) -7.60%
May-21-25 06:00AM	Solaris Enters into US$200 Million Financing Agreements with Royal Gold to Advance the Warintza Project (GlobeNewswire) -12.37%
May-20-25 08:00AM	SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase (GlobeNewswire) +10.86%
May-15-25 08:45AM	SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML (GlobeNewswire) +5.96%
May-13-25 04:05PM	SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -8.44% +7.09%
Apr-28-25 08:45AM	SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference (GlobeNewswire)
Apr-23-25 10:23AM	SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-08-25 08:45AM	SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML (GlobeNewswire)
Apr-05-25 12:37PM	Undercovered Dozen: Power Metals, Verses AI, TFS Financial, Nextdoor + (Seeking Alpha)
Mar-31-25 03:03PM	Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (Seeking Alpha)
Mar-20-25 04:05PM	SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-21-25 07:29AM	Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment (Clinical Trials Arena)
Feb-20-25 08:45AM	SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL (GlobeNewswire)
Jan-28-25 03:11PM	SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.02%
Jan-23-25 08:10AM	SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia (GlobeNewswire) -13.25%
Jan-08-25 08:20AM	SELLAS Announces Key Business Objectives for 2025 (GlobeNewswire) -9.49%
Jan-02-25 08:00AM	SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET (GlobeNewswire)
Dec-10-24 08:30AM	SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia (GlobeNewswire)
Dec-09-24 08:45AM	SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML (GlobeNewswire)
Nov-28-24 05:37AM	SELLAS announces data indicating key predictor of response to SLS009 in solid cancers (Clinical Trials Arena)
Nov-27-24 08:45AM	SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers (GlobeNewswire)
Nov-13-24 04:15PM	SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.93%
Nov-05-24 09:55AM	SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 (GlobeNewswire)
Oct-15-24 08:45AM	SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia (GlobeNewswire)

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

ScD h.c.Dr. Angelos M. Stergiou M.D.

Senior VP & CFOMr. John Thomas Burns CPA

MBADr. Dragan Cicic M.D.

VPMs. Stacy E. Yeung

Senior VP of Regulatory AffairsMr. Andrew Elnatan

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kalin Katherine Bach	Director	Nov 19 '25	Buy	1.59	63,400	100,806	104,400	Nov 21 08:45 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLS

SELLAS Life Sciences Group Inc

Upgrade your Finviz experience